RAPP Stock Forecast: Rapport Therapeutics, Inc. Price Predictions for 2026-2027
The 16 Wall Street analysts covering Rapport Therapeutics, Inc. hold a median 12-month price target of $64 — +174.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 66 of 100 as at 21 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Rapport Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (80): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Growth (26): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
RAPP stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on RAPP, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +174.2% from it.
Of the 20 most recent actions, 6 moved their price target up and 4 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 6 Nov 2026 | UBS | Maintains | Buy | — |
| 5 Nov 2026 | Guggenheim | Maintains | Buy | $70 → $66 |
| 5 Nov 2026 | UBS | Maintains | Buy | $71 → $64 |
| 5 Nov 2026 | Wells Fargo | Maintains | Overweight | $50 → $47 |
| 21 Oct 2026 | Guggenheim | Maintains | Buy | $65 → $70 |
| 21 Oct 2026 | Jones Trading | Maintains | Buy | $50 → $82 |
| 21 Oct 2026 | Wells Fargo | Maintains | Overweight | $51 → $50 |
| 20 Oct 2026 | BTIG | Maintains | Buy | $75 → $89 |
| 20 Oct 2026 | HC Wainwright & Co. | Reiterates | Buy | $66 |
| 15 Oct 2026 | UBS | Initiates | Buy | $71 |
| 15 Oct 2026 | Wolfe Research | Initiates | Outperform | — |
| 6 Oct 2026 | Guggenheim | Initiates | Buy | $65 |
| 16 Sept 2026 | BTIG | Maintains | Buy | $65 → $75 |
| 19 Aug 2026 | BTIG | Reiterates | Buy | $65 |
| 12 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $40 → $66 |
| 5 Aug 2026 | BTIG | Reiterates | Buy | $65 |
| 16 July 2026 | BTIG | Reiterates | Buy | $65 |
| 24 June 2026 | Leerink Partners | Initiates | Outperform | $52 |
| 21 May 2026 | BTIG | Maintains | Buy | — |
| 19 May 2026 | Truist Securities | Assumes | Buy | $44 → $56 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for RAPP.
This page is one stock. Monday covers all of them.
RAPP appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
RAPP vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Rapport Therapeutics, Inc. returned −13.7% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
RAPP analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 68.6×
- Price / book
- 2.8×
- EV / EBITDA
- —
Cheaper than 4% of US stocks
Cheaper than 32% of US stocks
- Revenue growth (YoY)
- −100.0%
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
Higher than 1% of US stocks
- Return on equity
- −33.3%
- Return on assets
- −22.0%
- Dividend yield
- —
Higher than 27% of US stocks
Higher than 18% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Rapport Therapeutics, Inc. has a market value of $1.4B and an enterprise value of $987.3M.
Revenue in the twelve months to 30 June 2026: $20.0M.
Net income over the same four quarters: −$137.2M, a −685.8% net margin.
Diluted earnings per share, trailing twelve months: −$3.04.
Free cash flow in the twelve months to 30 June 2026: −$97.1M.
Rapport Therapeutics, Inc. spent $5K on share buybacks in the twelve months to 30 June 2026.
Rapport Therapeutics, Inc. employs 84 people — $238K of revenue per employee.
Data provided by Twelve Data
RAPP and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at RAPP’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Rapport Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about RAPP
What is the RAPP stock price forecast for 2026-2027?
The 16 Wall Street analysts covering Rapport Therapeutics, Inc. have a median 12-month price target of $64, with estimates ranging from $47 to $89. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is RAPP stock a buy right now?
Of the 16 analysts covering Rapport Therapeutics, Inc., 16 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Rapport Therapeutics, Inc. 66 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank RAPP?
As at 21 Nov 2026, Rapport Therapeutics, Inc. ranks 66 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Value (80 of 100).
Will RAPP stock go up?
No one can know that. What the data says: the median 12-month target from 16 analysts implies +174.2% from the last close, and Ticker Nerd's factor model ranks Rapport Therapeutics, Inc. 66 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the RAPP stock forecast for 2030?
No analyst covering Rapport Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RAPP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $47 to $89 over the next 12 months.
How has RAPP stock performed over the past year?
Rapport Therapeutics, Inc. returned -13.7% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Rapport Therapeutics, Inc. do?
Rapport Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for central nervous system disorders. The company’s work centers on precision neuroscience, using its RAP technology platform to target receptor-associated proteins that help regulate neuronal signaling.
About Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for central nervous system disorders. The company’s work centers on precision neuroscience, using its RAP technology platform to target receptor-associated proteins that help regulate neuronal signaling. Its pipeline includes investigational programs for focal epilepsy, peripheral neuropathic pain, bipolar disorder, chronic pain, migraine, and hearing or vestibular disorders. Rapport Therapeutics also develops receptor-targeted candidates in areas such as AMPA receptor modulation and nicotinic acetylcholine receptor biology, reflecting a broad research effort across neurological and psychiatric conditions. Headquartered in Boston, Massachusetts, Rapport Therapeutics plays a specialized role in the biotechnology market by advancing targeted therapies designed for complex brain and nervous system diseases.
CEO Mr. Abraham N. Ceesay M.B.A. · 84 employees · United States · https://www.rapportrx.com